Dr. Arthur Kavanaugh: Safety and Rheumatoid Arthritis
Dr. Arthur Kavanaugh discusses safety issues related to JAK inhibitors at the ACR/ARHP Annual Meeting in San Diego.
Dr. Rachel Tate: Gender Bias in AS
Dr. Rachel Tate discusses gender bias in ankylosing spondylitis at the ACR/ARHP Annual Meeting in San Diego.
Dr. Allan Gibofsky: Cost of Care
Dr. Allan Gibofsky discusses the cost of care for patients at the ACR/ARHP Annual Meeting in San Diego.
Dr. Janet Pope: Cancer
Dr. Janet Pope discusses cancer data presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. Cassandra Calabrese: Checkpoint Inhibitor Therapy
Dr. Calabrese discusses IRAEs and checkpoint inhibitors at the ACR/ARHP Annual Meeting in San Diego.
Dr. Arthur Kavanaugh: Rheumatology Winter Clinical Symposium
Dr. Kavanaugh previews the 2018 Rheumatology Winter Clinical Symposium.
Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.
Dr. Bill Shergy: Giant Cell Arteritis
Dr. Bill Shergy discusses a seminar on giant cell arteritis at the ACR/ARHP Annual Meeting in San Diego.
Dr. Rachel Tate: Adalimumab and Disease Remission in non-Radiographic Axial SpA
Dr. Rachel Tate discusses the ABILITY 3 study at the ACR/ARHP Annual Meeting in San Diego.
Dr. Kathryn Dao: Giant Cell Arteritis and Vasculitis
Dr. Kathryn Dao discusses vasculitis and GCA at the ACR/ARHP Annual Meeting in San Diego.
Dr. Philip Mease: FUTURE 5 Study
Dr. Philip Mease discusses the FUTURE 5 study on psoriatic arthritis as presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. Paul Sufka: Pregnancy and Treatment
Dr. Paul Sufka discusses treatment of rheumatologic disease in patients who are pregnant at the ACR/ARHP Annual Meeting in San Diego.
Dr. Jack Cush and Dr. Pete Salzmann (Eli Lilly and Company): Pain as a Differentiator
Dr. Jack Cush and Dr. Pete Salzmann from Eli Lilly and Company discuss pain at the ACR/ARHP Annual Meeting in San Diego.
Dr. Rachel Tate: RISE Registry
Dr. Rachel Tate discusses the RISE Registry at the ACR/ARHP Annual Meeting in San Diego.
During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.
